MX2024002547A - Nuevo anticuerpo anti-muc1 y uso del mismo. - Google Patents
Nuevo anticuerpo anti-muc1 y uso del mismo.Info
- Publication number
- MX2024002547A MX2024002547A MX2024002547A MX2024002547A MX2024002547A MX 2024002547 A MX2024002547 A MX 2024002547A MX 2024002547 A MX2024002547 A MX 2024002547A MX 2024002547 A MX2024002547 A MX 2024002547A MX 2024002547 A MX2024002547 A MX 2024002547A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antigen
- binding fragment
- nucleic acid
- novel anti
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000036252 glycation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un nuevo anticuerpo y a uso del mismo y, más específicamente, a: un conjugado anticuerpo-fármaco o un anticuerpo biespecífico que comprende el anticuerpo producido sustituyendo una secuencia de anticuerpo existente o un fragmento de unión a antígeno del mismo, en donde el anticuerpo no tiene ninguna sustancia relacionada con la glicación generada en un proceso de producción; una composición farmacéutica que comprende el conjugado anticuerpo-fármaco o anticuerpo biespecífico para prevenir o tratar cáncer; un ácido nucleico que codifica el anticuerpo o un fragmento de unión a antígeno del mismo; un vector y una célula huésped que comprende el ácido nucleico; y un método para preparar un anticuerpo o un fragmento de unión a antígeno del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210113712 | 2021-08-27 | ||
| PCT/KR2022/012764 WO2023027534A1 (ko) | 2021-08-27 | 2022-08-25 | 신규 항 muc1항체 및 이의 용도 |
| KR1020220106864A KR20230034154A (ko) | 2021-08-27 | 2022-08-25 | 신규 항 muc1항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002547A true MX2024002547A (es) | 2024-03-14 |
Family
ID=85321916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002547A MX2024002547A (es) | 2021-08-27 | 2022-08-25 | Nuevo anticuerpo anti-muc1 y uso del mismo. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2024534148A (es) |
| AU (1) | AU2022333837A1 (es) |
| CA (1) | CA3230370A1 (es) |
| IL (1) | IL311090A (es) |
| MX (1) | MX2024002547A (es) |
| WO (1) | WO2023027534A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| BR112019019650A2 (pt) * | 2017-03-21 | 2020-06-30 | Peptron, Inc. | ligação de anticorpos especificamente à muc1 e utilização dos mesmos |
| US20220289863A1 (en) * | 2019-06-14 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
-
2022
- 2022-08-25 MX MX2024002547A patent/MX2024002547A/es unknown
- 2022-08-25 WO PCT/KR2022/012764 patent/WO2023027534A1/ko active Application Filing
- 2022-08-25 CA CA3230370A patent/CA3230370A1/en active Pending
- 2022-08-25 JP JP2024512218A patent/JP2024534148A/ja active Pending
- 2022-08-25 IL IL311090A patent/IL311090A/en unknown
- 2022-08-25 AU AU2022333837A patent/AU2022333837A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311090A (en) | 2024-04-01 |
| JP2024534148A (ja) | 2024-09-18 |
| CA3230370A1 (en) | 2023-03-02 |
| AU2022333837A1 (en) | 2024-03-14 |
| WO2023027534A1 (ko) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504553C2 (ru) | Антитела к her | |
| PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| MY198034A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| MX2021013850A (es) | Anticuerpo contra tigit y uso del mismo. | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| CR20220627A (es) | Moléculas agonistas de unión al antígeno cd28 que se derigen a her2 | |
| TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| CR20210548A (es) | Materiales y métodos para modular la inmunidad mediada por células t | |
| SA519401032B1 (ar) | (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه | |
| MX2022001682A (es) | Nuevos formatos de moleculas de union a antigenos. | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| WO2023202672A9 (en) | Antibodies targeting sirp-alpha and uses thereof | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| MX2024002547A (es) | Nuevo anticuerpo anti-muc1 y uso del mismo. | |
| ZA202104048B (en) | Anti-il-17a antibody and use thereof | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| SG11201806597XA (en) | ANTIBODY AGAINST EGFRvIII AND USE THEREOF | |
| MX2024003615A (es) | Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3). |